ABVC BioPharma, Inc.
ABVC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $1 | $0 |
| % Growth | 234.3% | -84.3% | 172.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | -$0 | $1 | $0 |
| % Margin | 99.9% | -98.1% | 70.5% | 98.6% |
| R&D Expenses | $0 | $1 | $3 | $1 |
| G&A Expenses | $5 | $6 | $13 | $11 |
| SG&A Expenses | $5 | $6 | $13 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5 | $7 | $16 | $12 |
| Operating Income | -$5 | -$7 | -$15 | -$12 |
| % Margin | -923.3% | -4,439.2% | -1,558.5% | -3,290.1% |
| Other Income/Exp. Net | -$1 | -$1 | -$0 | $0 |
| Pre-Tax Income | -$5 | -$8 | -$16 | -$11 |
| Tax Expense | -$0 | $0 | $1 | $1 |
| Net Income | -$5 | -$8 | -$16 | -$13 |
| % Margin | -962.1% | -5,109.3% | -1,693.5% | -3,608.5% |
| EPS | -0.42 | -1.8 | -5.2 | -5.1 |
| % Growth | 76.7% | 65.4% | -2% | – |
| EPS Diluted | -0.42 | -1.8 | -5.2 | -5.1 |
| Weighted Avg Shares Out | 12 | 4 | 3 | 3 |
| Weighted Avg Shares Out Dil | 12 | 4 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$6 | -$15 | -$11 |
| % Margin | -852.2% | -4,153.2% | -1,567% | -3,083.7% |